Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 101–200 of 1,004
Garcia-Aguilar, J., Smith, D. D., Avila, K., Bergsland, E. K., Chu, P., & Krieg, R. M. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182196e1f · Cited by 329
Golcher, H., Brunner, T. B., Witzigmann, H., Marti, L., Bechstein, W.-O., Bruns, C., Jungnickel, H., Schreiber, S., Grabenbauer, G. G., Meyer, T., et al. (2015) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0737-7 · Cited by 324
“[4, 5, 6] Moreover in rectal cancer it was found early, that a clear”
Self-citationSaigusa, S., Tanaka, K., Toiyama, Y., Yokoe, T., Okugawa, Y., Ioue, Y., Miki, C., & Kusunoki, M. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0617-z · Cited by 319
Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Chino, J., Annunziata, C. M., Beriwal, S., Bradfield, L., Erickson, B. A., Fields, E. C., Fitch, K., Harkenrider, M. M., Holschneider, C. H., Kamrava, M., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.04.002 · Cited by 313
Kim, T. H., Jeong, S.-Y., Choi, D. H., Kim, D. Y., Jung, K. H., Moon, S. H., Chang, H. J., Lim, S.-B., Choi, H. S., & Park, J.-G. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9696-x · Cited by 315
Chua, Y. J., Barbachano, Y., Cunningham, D., Oates, J. R., Brown, G., Wotherspoon, A., Tait, D., Massey, A., Tebbutt, N. C., & Chau, I. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70381-x · Cited by 319
Adjuvant Treatment of Colorectal Cancer
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.3.168 · Cited by 306
Garcia-Aguilar, J., Shi, Q., Thomas, C. R., Chan, E., Cataldo, P., Marcet, J., Medich, D., Pigazzi, A., Oommen, S., & Posner, M. C. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1933-7 · Cited by 304
Tulchinsky, H., Shmueli, E., Figer, A., Klausner, J. M., & Rabau, M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9892-3 · Cited by 304
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., Ledermann, J., & Sebag-Montefiore, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu147 · Cited by 299
Valentini, V., Aristei, C., Glimelius, B., Minsky, B. D., Beets-Tan, R., Borras, J. M., Haustermans, K., Maingon, P., Overgaard, J., Pahlman, L., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.027 · Cited by 300
Spaander, M. C. W., Zauber, A. G., Syngal, S., Blaser, M. J., Sung, J. J., You, Y. N., & Kuipers, E. J. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00432-7 · Cited by 288
Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis
Georgiou, P., Tan, E., Gouvas, N., Antoniou, A., Brown, G., Nicholls, R. J., & Tekkis, P. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70224-4 · Cited by 294
den Dulk, M., Marijnen, C. A. M., Collette, L., Putter, H., Påhlman, L., Folkesson, J., Bosset, J.-F., Rödel, C., Bujko, K., & van de Velde, C. J. H. (2009) · British Journal of Surgery · doi:10.1002/bjs.6694 · Cited by 297
Self-citationA Systematic Approach to the Interpretation of Preoperative Staging MRI for Rectal Cancer
Taylor, F. G. M., Swift, R. I., Blomqvist, L., & Brown, G. (2008) · American Journal of Roentgenology · doi:10.2214/ajr.08.1004 · Cited by 294
“The difficulties of overstaging of T3 tumors by endoscopic sonography have been documented [39].”
BackgroundAndreyev, H. J. N., Davidson, S. E., Gillespie, C., Allum, W. H., & Swarbrick, E. (2012) · Gut · doi:10.1136/gutjnl-2011-300563 · Cited by 290
Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
De Caluwé, L., Van Nieuwenhove, Y., & Ceelen, W. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006041.pub3 · Cited by 292
On behalf of the Royal Marsden Hospital, C. C. N., Burton, S., Brown, G., Daniels, I. R., Norman, A. R., Mason, B., & Cunningham, D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602947 · Cited by 291
“The debate over preoperative vs postoperative radiotherapy has been resolved (Sauer et al, 2004) and neoadjuvant therapy with either chemoradiation or long course chemotherapy has emerged as an effective treatment in the downstaging/downsizing of locally advanced tumours (Chau et al, 2003; Rodel et…”
BackgroundSainato, A., Cernusco Luna Nunzia, V., Valentini, V., De Paoli, A., Maurizi, E. R., Lupattelli, M., Aristei, C., Vidali, C., Conti, M., Galardi, A., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.10.006 · Cited by 288
“However, no improvement in the overall survival (OS) rate was observed, as the distant metastasis rate remained unchanged, ranging from 25% to 35% [1–7].”
BackgroundResultRödel, F., Hoffmann, J., Distel, L., Herrmann, M., Noisternig, T., Papadopoulos, T., Sauer, R., & Rödel, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3028 · Cited by 292
“These treatment protocols have been found to be effective in the treatment of primarily unresectable cancers and to preserve the sphincter in low-lying tumor therapy (1, 2).”
Self-citationLow Rectal Cancer: Classification and Standardization of Surgery
Rullier, E., Denost, Q., Vendrely, V., Rullier, A., & Laurent, C. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31827c4a8c · Cited by 292
Immunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
Sloothaak, D. A. M., Geijsen, D. E., van Leersum, N. J., Punt, C. J. A., Buskens, C. J., Bemelman, W. A., & Tanis, P. J. (2013) · British Journal of Surgery · doi:10.1002/bjs.9112 · Cited by 290
Gladdy, R. A., Qin, L.-X., Moraco, N., Edgar, M. A., Antonescu, C. R., Alektiar, K. M., Brennan, M. F., & Singer, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1728 · Cited by 289
Ng, S. S. M., Leung, K. L., Lee, J. F. Y., Yiu, R. Y. C., Li, J. C. M., Teoh, A. Y. B., & Leung, W. W. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9895-0 · Cited by 283
Occurrence of Second Cancers in Patients Treated With Radiotherapy for Rectal Cancer
Birgisson, H., Påhlman, L., Gunnarsson, U., & Glimelius, B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.543 · Cited by 282
Late Side Effects and Quality of Life After Radiotherapy for Rectal Cancer
Bruheim, K., Guren, M. G., Skovlund, E., Hjermstad, M. J., Dahl, O., Frykholm, G., Carlsen, E., & Tveit, K. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.010 · Cited by 278
A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Li, Y., Wang, J., Ma, X., Tan, L., Yan, Y., Xue, C., Hui, B., Liu, R., Ma, H., & Ren, J. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15438 · Cited by 275
“Comprehensive treatment is the only way to ensure the treatment efficacy for resectable stage II-III rectal cancer [4-9] (Table 1).”
BackgroundResultInfluentialTheis, V. S., Sripadam, R., Ramani, V., & Lal, S. (2010) · Clinical Oncology · doi:10.1016/j.clon.2009.10.003 · Cited by 268
“Indeed, higher incidences of both acute and chronic diarrhoea have been noted to occur after postoperative chemoradiotherapy compared with preoperative therapy [37].”
BackgroundNeoadjuvant radiotherapy for rectal cancer management
Feeney, G., Sehgal, R., Sheehan, M., Hogan, A., Regan, M., Joyce, M., & Kerin, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4850 · Cited by 269
Akiyoshi, T., Ueno, M., Matsueda, K., Konishi, T., Fujimoto, Y., Nagayama, S., Fukunaga, Y., Unno, T., Kano, A., Kuroyanagi, H., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3216-y · Cited by 265
Ueno, M., Oya, M., Azekura, K., Yamaguchi, T., & Muto, T. (2005) · British Journal of Surgery · doi:10.1002/bjs.4975 · Cited by 259
Trakarnsanga, A., Gönen, M., Shia, J., Nash, G. M., Temple, L. K., Guillem, J. G., Paty, P. B., Goodman, K. A., Wu, A., Gollub, M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju248 · Cited by 262
Curvo-Semedo, L., Lambregts, D. M. J., Maas, M., Thywissen, T., Mehsen, R. T., Lammering, G., Beets, G. L., Caseiro-Alves, F., & Beets-Tan, R. G. H. (2011) · Radiology · doi:10.1148/radiol.11102467 · Cited by 265
Nougaret, S., Reinhold, C., Mikhael, H. W., Rouanet, P., Bibeau, F., & Brown, G. (2013) · Radiology · doi:10.1148/radiol.13121361 · Cited by 264
“In several studies, CRT has resulted in 10%–20% complete tumor response rate (43,44).”
Quah, H., Chou, J. F., Gonen, M., Shia, J., Schrag, D., Saltz, L. B., Goodman, K. A., Minsky, B. D., Wong, W. D., & Weiser, M. R. (2008) · Cancer · doi:10.1002/cncr.23516 · Cited by 258
“The randomized trial reported by Sauer et al.(4) demonstrated significantly improved local control, reduced toxicity, and improved sphincter preservation when locally advanced rectal cancers are treated with preoperative rather than postoperative chemoradiation.”
BackgroundMethodInfluentialGeneralized Maximally Selected Statistics
Hothorn, T., & Zeileis, A. (2008) · Biometrics · doi:10.1111/j.1541-0420.2008.00995.x · Cited by 260
“Survival times of n = 349 patients from the preoperative arm of the CAO/ARO/AIO-94 trial (Sauer et al. 2004) with distant metastases found at surgery were excluded from this analysis).”
MethodA comprehensive framework for early-onset colorectal cancer research
Eng, C., Jácome, A. A., Agarwal, R., Hayat, M. H., Byndloss, M. X., Holowatyj, A. N., Bailey, C., & Lieu, C. H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00588-x · Cited by 241
Glynne-Jones, R., & Hughes, R. (2012) · British Journal of Surgery · doi:10.1002/bjs.8732 · Cited by 256
Ogura, A., Konishi, T., Beets, G. L., Cunningham, C., Garcia-Aguilar, J., Iversen, H., Toda, S., Lee, I. K., Lee, H. X., Uehara, K., et al. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.2172 · Cited by 254
Mohiuddin, M., Winter, K., Mitchell, E., Hanna, N., Yuen, A., Nichols, C., Shane, R., Hayostek, C., & Willett, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6095 · Cited by 255
cT3N0 Rectal Cancer: Potential Overtreatment With Preoperative Chemoradiotherapy Is Warranted
Guillem, J. G., Díaz-González, J. A., Minsky, B. D., Valentini, V., Jeong, S.-Y., Rodriguez-Bigas, M. A., Coco, C., Leon, R., Hernandez-Lizoain, J. L., Aristu, J. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5434 · Cited by 254
“ERUS was performed using a 7- to 10-MHz probe revealing the rectal mucosa,submucosa,andmuscularispropria.OnERUS,therectumappearsin five layers, as follows: ( 1 ) interface with the mucosa; (2) mucosa; (3) submucosa; (4) muscularis propria; and (5) interface with the perirectal fat.”
MethodStijns, R. C. H., de Graaf, E. J. R., Punt, C. J. A., Nagtegaal, I. D., Nuyttens, J. J. M. E., van Meerten, E., Tanis, P. J., de Hingh, I. H. J. T., van der Schelling, G. P., Acherman, Y., et al. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2018.3752 · Cited by 234
Gunderson, L. L., Jessup, J. M., Sargent, D. J., Greene, F. L., & Stewart, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9194 · Cited by 244
Battersby, N. J., Bouliotis, G., Emmertsen, K. J., Juul, T., Glynne-Jones, R., Branagan, G., Christensen, P., Laurberg, S., & Moran, B. J. (2018) · Gut · doi:10.1136/gutjnl-2016-312695 · Cited by 245
Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Cercek, A., Dos Santos Fernandes, G., Roxburgh, C. S., Ganesh, K., Ng, S., Sanchez-Vega, F., Yaeger, R., Segal, N. H., Reidy-Lagunes, D. L., Varghese, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3728 · Cited by 238
“Details of chemoradiation administration and scheduling are in the Supplementary Data.”
BackgroundLate adverse effects of radiation therapy for rectal cancer – a systematic overview
Birgisson, H., Påhlman, L., Gunnarsson, U., & Glimelius, B. (2007) · Acta Oncologica · doi:10.1080/02841860701348670 · Cited by 244
“Late urinary tract symptoms were rarely seen after rectal cancer surgery with or without RT [16,41,42,44,45].”
BackgroundMethodInfluentialS3-Leitlinie – Kolorektales Karzinom: Langversion 2.0 – November 2017–AWMF-Registernummer: 021/007OL
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T., Nothacker, M., Porschen, R., Rödel, C., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 241
Self-citationBiomarkers for Response to Neoadjuvant Chemoradiation for Rectal Cancer
Kuremsky, J. G., Tepper, J. E., & McLeod, H. L. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.003 · Cited by 238
Barbaro, B., Fiorucci, C., Tebala, C., Valentini, V., Gambacorta, M. A., Vecchio, F. M., Rizzo, G., Coco, C., Crucitti, A., Ratto, C., et al. (2009) · Radiology · doi:10.1148/radiol.2503080310 · Cited by 241
Zorcolo, L., Rosman, A. S., Restivo, A., Pisano, M., Nigri, G. R., Fancellu, A., & Melis, M. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2209-y · Cited by 237
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hofheinz, R.-D., Fokas, E., Benhaim, L., Price, T. J., Arnold, D., Beets-Tan, R., Guren, M. G., Hospers, G. A. P., Lonardi, S., Nagtegaal, I. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.528 · Cited by 205
colorectal cancer working group, C., & Chinese Society of Clinical Oncology (CSCO) (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.01.07 · Cited by 232
Definition and delineation of the clinical target volume for rectal cancer
Roels, S., Duthoy, W., Haustermans, K., Penninckx, F., Vandecaveye, V., Boterberg, T., & De Neve, W. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.02.050 · Cited by 231
Patel, U. B., Brown, G., Rutten, H., West, N., Sebag-Montefiore, D., Glynne-Jones, R., Rullier, E., Peeters, M., Van Cutsem, E., Ricci, S., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2309-3 · Cited by 232
“Preoperative CRT has been shown to be beneficial in reducing local recurrence rates and has become a standard of care for locally advanced rectal cancer.(2) Histopathologists grade tumor response in three ways: firstly assessment of the status of the circumferential resection margin (CRM), secondly the depth of tumor…”
BackgroundPatel, U. B., Blomqvist, L. K., Taylor, F., George, C., Guthrie, A., Bees, N., & Brown, G. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.8210 · Cited by 232
“This approach has been shown to decrease the postoperative tumor recurrence rate [3].”
BackgroundMulticenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer
Rödel, C., Liersch, T., Hermann, R. M., Arnold, D., Reese, T., Hipp, M., Fürst, A., Schwella, N., Bieker, M., Hellmich, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3675 · Cited by 230
Self-citationSystematic review of outcomes after intersphincteric resection for low rectal cancer
Martin, S. T., Heneghan, H. M., & Winter, D. C. (2012) · British Journal of Surgery · doi:10.1002/bjs.8677 · Cited by 226
Weiser, M. R., Quah, H.-M., Shia, J., Guillem, J. G., Paty, P. B., Temple, L. K., Goodman, K. A., Minsky, B. D., & Wong, W. D. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e318195e17c · Cited by 226
“Overall, the complication rate remains comparable with that in the series reported by Rullier et al(35) The most common complications following APR were perineal wound breakdown and delayed wound healing, as has been reported for patients treated with neoadjuvant therapy.(17,36) This study is subject to the limitation…”
BackgroundResultCercek, A., Goodman, K. A., Hajj, C., Weisberger, E., Segal, N. H., Reidy-Lagunes, D. L., Stadler, Z. K., Wu, A. J., Weiser, M. R., Paty, P. B., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0056 · Cited by 224
Kusters, M., Beets, G. L., van de Velde, C. J. H., Beets-Tan, R. G. H., Marijnen, C. A. M., Rutten, H. J. T., Putter, H., & Moriya, Y. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e318190a664 · Cited by 219
Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., Ariyan, C., Bassett, R., Carter, B., Daud, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30332-8 · Cited by 218
Kunnumakkara, A. B., Diagaradjane, P., Guha, S., Deorukhkar, A., Shentu, S., Aggarwal, B. B., & Krishnan, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4722 · Cited by 217
“preoperative chemoradiation therapy is an integral component of treatment because it reduces the risk of local recurrence and increases the probability of sphincter-preserving surgery (2).”
BackgroundShort-course preoperative radiotherapy with delayed surgery in rectal cancer – A retrospective study
Radu, C., Berglund, Å., Påhlman, L., & Glimelius, B. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.11.025 · Cited by 217
“Preoperative radiotherapy (RT), alone or with chemotherapy, is an established treatment for many patients with primary rectal cancer [1–3].”
BackgroundHabr-Gama, A., Perez, R. O., Sabbaga, J., Nadalin, W., São Julião, G. P., & Gama-Rodrigues, J. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181ba14ed · Cited by 221
“Tumor size reduction, in addition to partial or complete primary tumor and possible perirectal node sterilization, may lead to significant downstaging and increased rates of sphincter preservation.(1,2) Recently, the Read at the meeting of The American Society of Colon and Rectal Surgeons, Hollywood, Florida, May 2 to…”
BackgroundResultvan der Valk, M. J. M., Marijnen, C. A. M., van Etten, B., Dijkstra, E. A., Hilling, D. E., Kranenbarg, E. M.-K., Putter, H., Roodvoets, A. G. H., Bahadoer, R. R., Fokstuen, T., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.03.011 · Cited by 213
“The rationale for preoperative long-course CRT in patients with high-risk rectal cancer, in addition to reducing the risk of local recurrence, is to induce locoregional tumour downsizing and thereby increase the chance of radical (R0) total mesorectal excision [7,8].”
BackgroundPractice Parameters for the Management of Rectal Cancer (Revised)
(2005) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-0937-9 · Cited by 217
Cascini, G. L., Avallone, A., Delrio, P., Guida, C., Tatangelo, F., Marone, P., Aloj, L., Martinis, F. D., Comella, P., Parisi, V., et al. (2006) · PubMed · Cited by 231
Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer
O'Neill, B. D., Brown, G., Heald, R., Cunningham, D., & Tait, D. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70202-4 · Cited by 214
MR Imaging for Preoperative Evaluation of Primary Rectal Cancer: Practical Considerations
Kaur, H., Choi, H., You, Y. N., Rauch, G. M., Jensen, C. T., Hou, P., Chang, G. J., Skibber, J. M., & Ernst, R. D. (2012) · RadioGraphics · doi:10.1148/rg.322115122 · Cited by 215
“The timing of radiation therapy in the treatment of primary rectal cancer has been controversial, but randomized trials have shown that combined preoperative radiation therapy–TME reduces the prevalence of local recurrence from 8% to 2% and is superior to postoperative radiation therapy alone (6,7).”
BackgroundPre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma
Wong, R. K., Tandan, V., De Silva, S., & Figueredo, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002102.pub2 · Cited by 212
Habr-Gama, A., Perez, R. O., Proscurshim, I., Nunes dos Santos, R. M., Kiss, D., Gama-Rodrigues, J., & Cecconello, I. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.035 · Cited by 211
“Although neoadjuvant CRT has been considered the preferred treatment option for patients with distal rectal cancer, several aspects of the management of patients with this disease are unresolved (1).”
BackgroundEarly colorectal cancer: diagnosis, treatment and survivorship care
Buccafusca, G., Proserpio, I., Tralongo, A. C., Rametta Giuliano, S., & Tralongo, P. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.023 · Cited by 211
Circumferential resection margin as a prognostic factor in rectal cancer
Bernstein, T. E., Endreseth, B. H., Romundstad, P., & Wibe, A. (2009) · British Journal of Surgery · doi:10.1002/bjs.6739 · Cited by 209
Advances and Challenges in Treatment of Locally Advanced Rectal Cancer
Smith, J. J., & Garcia-Aguilar, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1054 · Cited by 211
de Campos-Lobato, L. F., Stocchi, L., da Luz Moreira, A., Geisler, D., Dietz, D. W., Lavery, I. C., Fazio, V. W., & Kalady, M. F. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1506-1 · Cited by 206
“In fact, treatment regimens associated with increased pCR rates did not correlate with improved oncologic outcomes in several prospective randomized trials.(2,38,44,45) The explanation for this discrepancy suggested by some authors is that a longer interval simply enhances the pathologist’s ability to identify dead ca…”
BackgroundLambrecht, M., Vandecaveye, V., De Keyzer, F., Roels, S., Penninckx, F., Van Cutsem, E., Claus, F., & Haustermans, K. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.063 · Cited by 206
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Saw, S. P. L., Ong, B.-H., Chua, K. L. M., Takano, A., & Tan, D. S. W. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00383-1 · Cited by 198
Management of Locally Advanced Rectal Cancer: ASCO Guideline
Scott, A. J., Kennedy, E. B., Berlin, J., Brown, G., Chalabi, M., Cho, M. T., Cusnir, M., Dorth, J., George, M., Kachnic, L. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01160 · Cited by 188
Total neoadjuvant therapy for rectal cancer: An emerging option
Ludmir, E. B., Palta, M., Willett, C. G., & Czito, B. G. (2017) · Cancer · doi:10.1002/cncr.30600 · Cited by 202
“Particular emphasis has been placed on the role of improving the concurrent chemotherapy component of neoadjuvant CRT.8,63,64 To that end, a recently presented phase 2 clinical trial platform is aiming to identify novel sensitizing agents administered with neoadjuvant CRT that might improve disease-related outcomes.65…”
BackgroundMethodInfluentialSwitching on prodrugs using radiotherapy
Geng, J., Zhang, Y., Gao, Q., Neumann, K., Dong, H., Porter, H., Potter, M., Ren, H., Argyle, D., & Bradley, M. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00711-4 · Cited by 196
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
Uprety, D., Mandrekar, S. J., Wigle, D., Roden, A. C., & Adjei, A. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.020 · Cited by 201
Joye, I., Deroose, C. M., Vandecaveye, V., & Haustermans, K. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.11.026 · Cited by 197
Preoperative staging of rectal cancer
Smith, N., & Brown, G. (2008) · Acta Oncologica · doi:10.1080/02841860701697720 · Cited by 196
“[10] Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C,”
BackgroundThe STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
“STAT3 has been described as a key mediator of chemoradiotherapy (CRT) resistance in numerous cancers, including gliomas [37–39], breast cancer [40–43], colorectal cancer [44,45], and prostate and cervical cancers [42], in addition to HNSCC.”
BackgroundNeoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
Assifi, M. M., Lu, X., Eibl, G., Reber, H. A., Li, G., & Hines, O. J. (2011) · Surgery · doi:10.1016/j.surg.2011.07.006 · Cited by 193
Yeo, S.-G., Kim, D. Y., Kim, T. H., Chang, H. J., Oh, J. H., Park, W., Choi, D. H., Nam, H., Kim, J.-S., Cho, M.-J., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f3f1b1 · Cited by 191
“Eligibility Eligibility criteria were as follows: before CRT: (1) histologically confirmed rectal adenocarcinoma; (2) cT3–4 or cN+ classification; (3) no distant metastasis; and (4) no prior systemic therapy (chemotherapy or immunotherapy) or radiotherapy; after CRT: (5) curative radical resection; (6) post-CRT pathol…”
BackgroundVliegen, R. F. A., Beets, G. L., Lammering, G., Dresen, R. C., Rutten, H. J., Kessels, A. G., Oei, T.-K., de Bruïne, A. P., van Engelshoven, J. M. A., & Beets-Tan, R. G. H. (2008) · Radiology · doi:10.1148/radiol.2462070042 · Cited by 191
Loos, M., Quentmeier, P., Schuster, T., Nitsche, U., Gertler, R., Keerl, A., Kocher, T., Friess, H., & Rosenberg, R. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2827-z · Cited by 190
De Cecco, C. N., Ganeshan, B., Ciolina, M., Rengo, M., Meinel, F. G., Musio, D., De Felice, F., Raffetto, N., Tombolini, V., & Laghi, A. (2015) · Investigative Radiology · doi:10.1097/rli.0000000000000116 · Cited by 188
“Copyright © 2015 Wolters Kluwer H Neoadjuvant chemoradiotherapy (CRT) followed by radical surgery using total mesorectal excision (TME) is the therapy of choice for locally advanced rectal cancers.(1,2) This combined treatment is able to reduce local pelvic recurrence to rate lower than 10%.”
BackgroundBattersby, N. J., Juul, T., Christensen, P., Janjua, A. Z., Branagan, G., Emmertsen, K. J., Norton, C., Hughes, R., Laurberg, S., & Moran, B. J. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000552 · Cited by 185
Gerard, J.-P., Barbet, N., Schiappa, R., Magné, N., Martel, I., Mineur, L., Deberne, M., Zilli, T., Dhadda, A., & Myint, A. S. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00392-2 · Cited by 184
MRI for Detection of Extramural Vascular Invasion in Rectal Cancer
Smith, N. J., Shihab, O., Arnaout, A., Swift, R. I., & Brown, G. (2008) · American Journal of Roentgenology · doi:10.2214/ajr.08.1298 · Cited by 182
“MRI-based staging is increasingly recommended [3] because patients at highest risk can undergo preoperative adjuvant treatment, which has a better outcome and less toxicity than does postoperative treatment [4].”
BackgroundSandur, S. K., Deorukhkar, A., Pandey, M. K., Pabón, A. M., Shentu, S., Guha, S., Aggarwal, B. B., & Krishnan, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.034 · Cited by 183
“Rectal cancer frequently presents at a locally advanced stage where pre-operative chemoradiation therapy (CRT) is used to downstage the tumor, make it more resectable, and render it less likely to recur after surgery (1).”
Chemoradiotherapy for Rectal Cancer: An Updated Analysis of Factors Affecting Pathological Response
Sanghera, P., Wong, D. W. Y., McConkey, C. C., Geh, J. I., & Hartley, A. (2008) · Clinical Oncology · doi:10.1016/j.clon.2007.11.013 · Cited by 182
Wijeysundera, D. N., Austin, P. C., Hux, J. E., Beattie, W. S., & Laupacis, A. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.07.006 · Cited by 184
Crane, C. H., Eng, C., Feig, B. W., Das, P., Skibber, J. M., Chang, G. J., Wolff, R. A., Krishnan, S., Hamilton, S., Janjan, N. A., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.037 · Cited by 183
den Dulk, M., Putter, H., Collette, L., Marijnen, C. A. M., Folkesson, J., Bosset, J.-F., Rödel, C., Bujko, K., Påhlman, L., & van de Velde, C. J. H. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.039 · Cited by 183
Self-citation
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.